Suscribirse

Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease - 31/07/15

Doi : 10.1016/j.hlc.2015.03.020 
Paul Nestel, MD, FRACP, FCSANZ, FTSE a, , Peter Clifton, MBBS, PhD, FRACP b, David Colquhoun, MBBS, FRACP, FCSANZ c, Manny Noakes, PhD d, Trevor A. Mori, PhD e, David Sullivan, MBBS, FRACP, FRCPA, FCSANZ f, Beth Thomas, BHlthSci g
a Baker IDI Heart & Diabetes Institute, Melbourne, Vic Australia 
b School of Pharmacy and Medical Sciences, Sansom Institute, University of South Australia, Adelaide, SA Australia 
c Wesley Medical Centre, Greenslopes Hospital, and University of Queensland, Brisbane, Qld, Australia 
d Animal, Food and Health Sciences, CSIRO, Australia 
e School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia 
f NHMRC Clinical Trials Centre, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia 
g National Heart Foundation of Australia, Australia 

Corresponding author at: Baker IDI Heart & Diabetes Institute, PO Box 6492 Melbourne 8008, Australia

Resumen

Background

The National Heart Foundation of Australia (NHFA) 2008 review on omega-3 long-chain polyunsaturated fatty acids (LCPUFA) made recommendations with respect to supplementation for primary and secondary prevention of cardiovascular disease. Since then, new findings have been published regarding the relationship between omega-3 polyunsaturated fatty acids, including supplementation, and cardiovascular health.

Methods

A literature search was undertaken in PubMed and Medline, for literature published between January 1, 2007 and August 31, 2013.

Results and Conclusions

A total of eight research questions were developed and, using the National Health and Medical Research Council's evidence assessment framework, conclusions were made in relation to dietary intake of fish and omega-3 LCPUFA for cardiovascular health.

In the evidence published since 2007, this summary of evidence concludes that dietary intake of fish was found to be mostly consistent with respect to protection from heart disease and stroke. Higher fish intake was associated with lower incident rates of heart failure in addition to lower sudden cardiac death, stroke and myocardial infarction.

In relation to omega-3 LCPUFA supplementation, neither a beneficial nor adverse effect was demonstrated in primary or secondary prevention of coronary heart disease (CHD). Although the evidence continues to be positive for the role of omega-3 LCPUFA in the treatment of hypertriglyceridaemia and a modest positive benefit in heart failure. No further evidence was found to support the consumption of 2g alpha-linolenic acid (ALA)/day over the current Australian guidelines for 1g/day.

El texto completo de este artículo está disponible en PDF.

Keywords : Fish oil, Omega-3 polyunsaturated fatty acid supplements, Fish consumption, Cardiovascular disease, Recent evidence.


Esquema


© 2015  Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 24 - N° 8

P. 769-779 - août 2015 Regresar al número
Artículo precedente Artículo precedente
  • Should We Recommend Exercise after the Fontan Procedure?
  • Nigel Sutherland, Bryn Jones, Yves d’Udekem
| Artículo siguiente Artículo siguiente
  • ALDH1 Expression and the Prognosis of Lung Cancer: A Systematic Review and Meta-Analysis
  • Dong Wei, Jing-Jing Peng, Hui Gao, Tao Zhang, Yong Tan, Yong-He Hu

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.